ストックスクリーナーアプリを入手
6.89
4.39%
0.29
アフターアワーズ：
6.89
前日終値:
$6.60
開ける：
$6.74
24時間の取引高:
63,192
Relative Volume:
3.53
時価総額：
$26.04M
収益：
-
当期純損益:
$-24.77M
株価収益率:
-9.4384
EPS:
-0.73
ネットキャッシュフロー:
$-17.36M
1週間 パフォーマンス:
-29.34%
1か月 パフォーマンス:
+9.37%
6か月 パフォーマンス:
-25.44%
1年 パフォーマンス:
-18.86%
1日の値動き範囲:
$6.10
$7.21
1週間の範囲:
$4.5601
$9.80
52週間の値動き範囲:
$4.5601
$19.00
Mink Therapeutics Inc Stock (INKT) Company Profile
INKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
6.89 | 26.04M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Significant Increase in Short Interest - MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Mink Therapeutics stock hits 52-week high at $8.84 By Investing.com - Investing.com Canada
MiNK Therapeutics announces reverse stock split - MSN
MiNK Therapeutics (NASDAQ:INKT) Shares to Reverse Split on Tuesday, January 28th - Defense World
MiNK Therapeutics, Inc. Announces a Presentation at the American Society of Clinical Oncology Gastrointestinal Cancers - Marketscreener.com
MiNK Therapeutics presents cancer study at ASCO GI - Investing.com India
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - The Manila Times
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics announces reverse stock split By Investing.com - Investing.com UK
Kinaxis Inc. (TSE:KXS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
MiNK Therapeutics (NASDAQ:INKT) vs. Evaxion Biotech A/S (NASDAQ:EVAX) Head to Head Analysis - Defense World
Nerdy, Inc. (NYSE:NRDY) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Stock Market Movers Today • Top Gainers & Losers - Benzinga
MML Investors Services LLC Acquires Shares of 12,147 Sabre Co. (NASDAQ:SABR) - Defense World
Carbon Streaming (OTCMKTS:OFSTF) Stock Price Up 5.5% – What’s Next? - Defense World
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire
Claire's Place Foundation Wraps up 2024 with Record-Breaking Events & Exciting Announcements for 2025 - The Manila Times
Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges - Investing.com Australia
Mink Ventures Commences Diamond Drill Program at Warren Nickel Copper Cobalt Project, Timmins, Ontario - Yahoo Finance
ATEX Resources (OTCMKTS:ECRTF) Stock Price Down 0.7% – Here’s Why - Defense World
Domo’s (DOMO) Market Outperform Rating Reiterated at JMP Securities - Defense World
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering - BioSpace
Arovella heads toward clinic with CAR-19-iNKT cells - BioWorld Online
Comparing MiNK Therapeutics (NASDAQ:INKT) & Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Geenex Developed Mink Solar Project Approved by Ohio Power Siting Board - Yahoo Finance
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Midwest Energy Emissions Becomes Birchtech Corp. and Announces Equity Incentive Plan AmendmentsOn October 29, 2024, Birchtech Corp. (formerly Midwest Energy Emissions Corp.) filed a Form 8-K with the SEC, detailing recent corporate changes and u - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
Mink Ventures Receives $89,160 in Non-Dilutive Capital With OJEP Grant for Warren Nickel Copper Cobalt Project - Yahoo Finance
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):